MRC1 and cancer: These inherent study limitations notwithstanding, we will continue to improve our model to more accurately predict outcomes in the immunotherapy-specific setting of individualized cancer patients, potentially through the inclusion of additional biomarkers, as bioactive molecules such as IFNγ, CD206, CX3CR1, CD1D, and iNOS, along with cell-mediated mechanisms known to have an effect on immune checkpoint inhibitor therapy (Park et al., 2018; Gubin et al., 2018).